Leader in biomarker research celebrates opening of new facility in Claymont

Claymont – As a company engaged in developing revolutionary technology and groundbreaking testing, CD Diagnostics Inc. is the perfect fit for Delaware’s growing biotech industry.

And as a leader in biomarker research and immunoassay development that enhances diagnoses and improves patient outcomes, there will be plenty of room for the company to grow now that it has settled into its new headquarters facility in Claymont.

Delaware Economic Director Alan Levin joined Rick Birkmeyer, President and Chief Executive Officer of CD Diagnostics, and other company and government officials for a ribbon cutting Wednesday to celebrate the opening of CD Diagnostics’ new 20,000-square-foot space in Brandywine Corporate Center 1 in Claymont.

“Delaware is home to a growing collection of successful biotech companies, which range from homegrown start-ups to transplants that made our state their home, and we’re proud to have CD Diagnostics move here,” Gov. Jack Markell said. “As their successful work has shown, CD Diagnostics is ahead of the curve in their field. We look forward to their ongoing research, development of products and continued growth in the First State.”

CD Diagnostics recently consolidated offices in Wynnewood, Pennsylvania, and Logan Township, New Jersey, into its new Delaware location, where research & development, product manufacturing and business administration are housed under one roof.

“We are excited about our move to Delaware,” says CEO Richard Birkmeyer. “This area provides access to an outstanding work force, easy access for our corporate partners, and interaction with a thriving economic and scientific community.”

CD Diagnostics is also the parent company of Citrano Medical Laboratories, a CLIA-certified (Clinical Laboratory Improvement Amendments) laboratory in Towson, Maryland, that has offered comprehensive clinical testing services to its clients for 39 years. Together, the companies develop and manufacture immunoassays in both laboratory and point of care formats.

The company is also forging new paths in the research of biomarkers – proteins which reflect the body’s response to a specific disease state. The company can develop tests with a high degree of accuracy and precision by identifying and measuring the concentrations of these proteins. This is the technology behind Synovasure®, a product developed by the company for the diagnosis of periprosthetic joint infection.

“We founded the company to develop and commercialize innovative tests for disease,” says Dr. Carl Deirmengian, Chief Medical Officer. “The commercial launch of our first synovial fluid biomarker assay in November 2013 has already made a clinical impact, as the Synovasure® Test has been very well received by othopaedic surgeons across the country. More importantly, it provides the physician with a new diagnostic tool that enables physicians to improve patient outcomes. With the assistance of Delaware, we have built an advanced manufacturing facility that will aid in accelerating the development of several new products.”

CD Diagnostics was awarded a Delaware Strategic Fund Performance grant in the amount of $500,000 for the creation of 170 jobs by 2016.

“CD Diagnostics uses the latest technology and practices to create the products of tomorrow. They are one of several companies here in Delaware that are redefining what it means to be a manufacturer through their use of advanced laboratories and techniques,” said Alan Levin, Director of the Delaware Economic Development Office. “Through the use of pioneering research and development and exhaustive networking in the medical field, there is no limit to their potential.”

About the Delaware Economic Development Office
The Delaware Economic Development Office is an executive state agency responsible for attracting new investors and businesses to the state, promoting the expansion of existing industry, assisting small and minority-owned businesses, promoting and developing tourism and creating new and improved employment opportunities for all citizens of the State. Visit dedo.delaware.gov.

About CD Diagnostics
CD Diagnostics combines expertise in immunoassay development with biomarker research, patented technology, and GMP manufacturing to deliver a range of products that address challenging diagnostic issues. The company improves patient outcomes by providing more accurate and rapid diagnosis. CD Diagnostics recently completed the acquisition of Citrano Medical Laboratories, a CLIA-certified laboratory that has provided comprehensive clinical testing services to clients for 39 years. The CLIA laboratory and sample acquisition programs with major hospitals and medical research institutions facilitate the rapid development and commercialization of laboratory developed tests. The first laboratory developed test for periprosthetic joint infection, Synovasure, LDT, was developed with Zimmer and released in November 2012. CD Diagnostics is developing additional tests for other disease states and use as companion diagnostics. Visit www.cddiagnostics.com.

Print